CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.
Source link
What’s your Reaction?
+1
+1
+1
+1